The information of our products contained in this section is partial and for orientation purposes only. A health care professional or certified physician must always be consulted for an appropriate diagnosis and use of these medications.

 BRAND                                                  DRUG SUBSTANCE                                                  PRESENTATION

           CIGANCLOR®                                                     Ganciclovir                                                                                500 mg vial x 1
Made in Argentina
For sale under filed prescription
Ganciclovir
Composition:
 Each vial contains: Ganciclovir (as sodium salt) 500 mg.
Therapeutic Action:
 Anti-cytomegalovirus.
Dosage and Administration:
To be administered only as IV perfusion.
Adults and Adolescents:
 

Induction: IV infusion: 5 mg per kg of body weight, administered during at least 1 hour, every 12 hours for 14 to 21 days. Intravitreal Injection: 200 mcg in 0.1 ml twice a week for 3 weeks. Maintenance: IV infusion: 5 mg per kg of body weight once a day, administered during at least 1 hour, once a day on week days, or 6 mg per kg of body weight, administered during at least 1 hour, once a day 5 days a week. Intravitreal Injection: 200 mcg in 0.1 ml once a week.

 
Pediatric Use:
 

Dosing was not established for pediatric use.

Presentation:
 Package containing 1 vial.
           LAZINEVIR®                                                        Lamivudine / Zidovudine / Nevirapine                                    150 mg / 300 mg / 200 mg coat. tabs. x 60
Made in Argentina
For sale under filed prescriptiontacc-es
Lamivudine + Zidovudine + Nevirapine
Composition:
 Each LAZINEVIR coated tablet contains: Lamivudine 150 mg, Zidovudine 300 mg and Nevirapine 200 mg.
Therapeutic Action:
 Antiretroviral fixed-dose combination. Two of LAZINEVIR active ingredients (lamivudine and zidovudine) belong to a group of antiretrovirals known as nucleoside reverse transcriptase inhibitor, and the third one (nevirapine) belongs to the group of nucleoside non analog inverse transcriptase inhibitor.
Indications:
 LAZINEVIR is indicated for the treatment of the infection caused by HIV, once the patients stabilized the maintenance regimen with nevirapine 200 mg per day and showed adequate nevirapine tolerability.
Dosage and Administration:
Adults with no less than 50 kg of body weight and children older than 12 years of age: One tablet of LAZINEVIR twice a day. If it is clinically indicated to reduce the dose of any of the components, or if a nevirapine induction period needs to be established, administer 200 mg of Nevirapine once a day during the first 14 days to diminish the possibility of rash. Separated preparations of each drug must be administered until the dose is adapted to the fixed-dose combination. Patient Monitoring: Full blood and urine tests must be done. Tests also have to include the hepatic function before the treatment is started and at appropriate intervals while the treatment is in progress. If abnormalities occur, they must be assessed and eventually the medication must be interrupted to restart dosing with non-combination preparations. There are no data available regarding dosing recommended for Nevirapine in patients with hepatic or renal dysfunction or undergoing dialysis.
 
Presentation:
 Packages containing 60 coated tablets.
           LEUZAN®                                                            Tenofovir DF                                                                               300 mg coat. tabs. x 30
Made in Argentina
For sale under filed prescriptiontacc-es
Tenofovir DF
Composition:
 Each LEUZAN coated tablet contains tenofovir disoproxil fumarate (tenofovir disoproxil 245 mg as, or as Tenofovir 136 mg) 300.00 mg.
Therapeutic Action:
 Antiretroviral inhibitor of HIV-1 reverse transcriptase and HBV polymerase inhibitor. ATC Code: J05AF07.
Indications:
 HIV-1 Infection: Tenofovir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. The following points should be considered when initiating therapy with tenofovir for the treatment of HIV-1 infection: Tenofovir should not be used in combination with fixed-dose tablets of emtricitabine + tenofovir or emtricitabine + tenofovir + efavirenz – Chronic Hepatitis B: Tenofovir is indicated for the treatment of chronic hepatitis B in adults. The following points should be considered when initiating therapy with tenofovir for the treatment of HBV infection: This indication is based primarily on data from the treatment of naïve patients treated with nucleoside and a small number of patients who had previously received lamivudine or adefovir. Patients were adults with chronic hepatitis B HBAg-positive and HBeAg-negative with compensated liver disease. The number of patients for clinical trials that had substitutions associated with lamivudine or adefovir in the baseline was too small to reach conclusions on effectiveness. Tenofovir has not been evaluated in patients with decompensated liver disease.
Dosage and Mode of Administration
Recommended dosage: For treatment of HIV-1 or hepatitis B infection: a dose of tenofovir disoproxil fumarate is 300 mg once a day orally, with or without food. In the treatment of chronic hepatitis B is unknown optimal duration of treatment - Dose adjustment for renal impairment: There were significant increases in drug exposure when tenofovir was administered to patients with moderate to severe renal impairment. Therefore, the dosing interval of tenofovir should be adjusted in patients with baseline creatinine clearance <50 ml / min. The safety and efficacy of these recommendations to adjust the dosing interval have not been clinically evaluated, therefore, clinical response to treatment and renal function should be monitored carefully in these patients. No dosage adjustment is needed in patients with mild renal insufficiency (creatinine clearance 50-80 ml / min). More attention should be routine monitoring of calculated creatinine clearance and serum phosphorus in patients with mild renal insufficiency. Dose adjustment for patients with impaired creatinine clearance: Interval recommended dose of 300 mg. for creatinine clearance 30-49 ml / min, every 48 hours., 10-29 ml / min: twice a week hemodialysis patients: every 7 days, assuming three hemodialysis sessions of approximately 4 hours per week . Tenofovir should be administered after completion of dialysis. The pharmacokinetics of tenofovir have not been evaluated in patients not receiving hemodialysis with creatinine clearance <10 ml / min. And therefore, no recommendations are available for these patients.
 
Presentation:
 Packages containing 30 coated tablets.
 
           MIVUTEN®                                                           Lamivudine / Tenofovir DF                                                       300 mg / 300 mg coat. tabs. x 30
Made in Argentina
For sale under filed prescriptiontacc-es
Lamivudine + Tenofovir DF
Composition:
 Each MIVUTEN coated tablet contains Lamivudine 300 mg and Tenofovir disoproxil fumarate 300 mg.
Therapeutic Action:
 A combination of antiretrovirals to treat HIV infection. ATC Code: J05AR
Indications:
 Indicated for the treatment of HIV infection in combination with other antiretroviral agents./div>
Dosage and Administration:
The usual dose is one tablet once a day and can be combined with other antiretroviral drugs.
Presentation:
 Packages containing 30 coated tablets.
 
           PROBIRASE®                                                      Sofosbuvir                                                                                 400 mg coat. tabs. x 28
Made in Argentina

For sale under filed prescriptiontacc-es

Sofosbuvir
Composition:
 Each coated tablet of Probirase contains sofosbuvir  400 mg.
Therapeutic Action:
 Direct action antiviral. ATC code: J05AX15
Indications:

Sofosbuvir is indicated for the treatment of infection by genotypes 1, 2, 3 or 4 of the chronic
Hepatitis C virus (HCV) as a component in the combined antiviral treatment regimen.

 Dosage and Administration:

The recommended sofosbuvir dose is one 400 mg film-coated tablet, oral, once daily with or without food.
Sofosbuvir should be administered in combination with ribavirin or in combination with pegylated interferon and ribavirin for the treatment of HCV. The recommended treatment regimen and the duration of the sofosbuvir combination therapy are indicated in the following table.

 

Patient population 

Treatment regimen

Duration

Genotype 1 or 4

Sofosbuvir + peginterferon alfa + ribavirin

12 weeks

Genotype 2

Sofosbuvir + ribavirin

12 weeks

Genotype 3

Sofosbuvir + ribavirin

24 weeks

 
a. See recommended dose for patients with genotype 1 or 4 HCV in the prescribing information for peginterferon alfa.
b. Ribavirin dose is administered based on weight (less than 75 kg = 1000 mg, and equal or higher than 75 kg = 1200 mg). The daily dose of ribavirin is administered orally in two divided doses with food. Patients with renal impairment (CrCl equal to or less than 50 ml/min) require a dose reduction of ribavirin; see ribavirin prescribing information.
For patients co-infected with HCV/HIV-1, should be followed the recommendations for dosage of the table.
Patients with HCV genotype 1 who are not candidates for interferon-based regimen: sofosbuvir in combination with ribavirin for 24 weeks may be considered as a therapeutic option for patients with genotype 1 infection who are not eligible to receive an interferon-based regimen. The choice of treatment should be guided by an assessment of the potential risks and benefits for each patient.
Patients with hepatocellular carcinoma awaiting liver transplantation: Administrate sofosbuvir in combination with ribavirin for up to 48 weeks or until liver transplantation, whichever comes first, to prevent HCV reinfection after transplantation.
Presentations:
Packages containing 2 blisters of 14 film-coated tablets each.

 

           PROTEASE®                                                       Nevirapine                                                                                  200 mg coat. tabs. x 60
Made in Argentina
For sale under prescriptiontacc-es
Nevirapine
Composition:
 Each tablet contains: Nevirapine 200 mg.
Therapeutic Action:
 Antiviral
Dosage and Administration:
The recommended dose for nevirapine is one 200 mg tablet a day the first 14 days (this induction period is used since it was observed to decrease the frequency of rash), followed by one 200 mg tablet twice a day, in combination with nucleoside analog antiretroviral agents.
 
Presentation:
 Package containing 60 tablets.
 
           SELMIVIR®                                                          Abacavir / Lamivudine                                                              600 mg / 300 mg coat. tabs. x 30
Made in Argentina
For sale under filed prescriptiontacc-es
Lamivudine + Abacavir
Composition:
 Each tablet of SELMIVIR contains: 300 mg lamivudine, 600 mg abacavir (as sulfate).
Therapeutic Action:
 A combination of antiretrovirals to treat HIV infection. ATC Code: J05AR02
Indications:
 Indicated for the treatment of HIV infection in combination with other antiretroviral agents.
Dosage and Administration:
The mThe usual dose for adults and adolescents is one tablet once a day and may be combined with other antiretroviral drugs. It should not be administered to adults or adolescents who weigh less than 40 kg because it is a fixed-dose tablet whose dose can not be reduced. It can be administered with or without food. This fixed-dose tablet should not be prescribed for patients requiring dose adjustments. Separate preparations of abacavir or lamivudine are available in cases where discontinuation or dose adjustment of one of the active substances are indicated. In these cases the physician should refer the individual product information.
 
Presentation:
 Package containing 30 coated tablets.
 
           TRIVENZ®                                                           Efavirenz / Emtricitabine / Tenofovir DF                                  600 mg / 200 mg / 300 mg coat. tabs. x 30
Made in Argentina
For sale under filed prescriptiontacc-es
Efavirenz  + Emtricitabine + Tenofovir DF

 

Composition:

Each tablet of Trivenz contains: 600 mg Efavirenz , 200 mg Emtricitabine, 300 mgTenofovir DF.

Therapeutic Action: 

A combination of antiretrovirals to treat HIV infection. 

Code ATC: J05AR06.

Indications:

Trivenz is indicated alone as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults or pediatric patients of 12 years of age or older.

Dossage and Administration:
 
Adults and pediatric patients of 12 years of age or older with a minimum body weight of 40 kg:

The recommended dose of Trivenz is one tablet taken orally once daily with an empty stomach. Bedtime administration may improve the tolerability of  nervous system symptoms.

Kidney insufficiency: Due to Trivenz is a fixed-dose combination, it should not be prescribed for patients requiring dose adjustments such as those with moderate or severe renal insufficiency (Creatinine clearance less than 50mL / min). Coadministration with Rifampin: When Trivenz is administered with rifampin to patients with a weight of  50 kg or more, an additional dose of 200 mg / day efavirenz is recommended.

Presentation:

Package containing 30 coated tablets.

 
           VIRONTAR®                                                        Darunavir / Ritonavir                                                                 600 mg / 100 mg coat. tabs. x 60
Made in Argentina
For sale under filed prescriptiontacc-es
Darunavir + Ritonavir
Composition:
 Each coated tablet of Virontar contains Darunavir 600 mg and Ritonavir 100 mg.
Therapeutic Action:
 Antiviral for systemic use. ATC Code: J05AR.
Indications:
 Virontar co-administered with other antiretroviral agents, is indicated for the treatment of infection by the human immunodeficiency virus (HIV-1).
Dosing and Administration:
Genotypic tests are recommended for patients with prior antiretroviral therapy. However, when genotypic testing is not feasible, two daily doses of Virontar are recommended. Patients with hepatic impairment: No dose adjustment is required in patients with mild or moderate hepatic impairment. No information is available on the use of Virontar when co-administered to patients with severe hepatic impairment, therefore Virontar use is not recommended in patients with severe hepatic impairment.
 
Presentation:
Packages containing 60 coated tablets.
 
           VIRONTAR®N                                                     Darunavir / Ritonavir                                                                  800 mg / 100 mg coat. tabs. x 30
Made in Argentina
For sale under filed prescriptiontacc-es
Ritonavir + Darunavir
Composition:
 Each coated tablet of Virontar N contains Darunavir 800 mg. and Ritonavir 100 mg.
Therapeutic Action:
 Antiviral for systemic use. ATC code: J05AR
Indications:

Virontar N co-administered with other antiretroviral agents, is indicated for the treatment of infection by the human immunodeficiency virus (HIV-1 in: Adult patients without previous antiretroviral treatment (naïve). Adult patients with previous antiretroviral treatment without mutations associated with resistance to darunavir. In previously untreated adult patients should be considered the following points when starting Virontar N therapy: Treatment history and, when available, genotypic or phenotypic tests should guide the use of Virontar N. The use of other active agents with Virontar N is associated with an increased possibility of response to treatment. -->

Dosage and Administration:
Adult patients without previous antiretroviral treatment (naïve):
 

The recommended dose is a coated tablet of Virontar N (darunavir 800 mg / ritonavir 100 mg) once daily administered with food.

 
Adult patients with previous antiretroviral treatment:
 

EIn patients previously treated with antiretroviral treatment without mutations associated with resistance to darunavir (V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V and L89V)can be used a coated tablet of Virontar N administered once a day with food. For patients with prior antiretroviral therapy is recommended genotypic testing.

 
Patients with hepatic impairment:
 

No dose adjustment is required in patients with mild or moderate hepatic impairment. No information available on the use of Virontar N when co-administered to patients with severe hepatic impairment, therefore the use of Virontar N is not recommended in patients with severe hepatic impairment.

Presentation:
 Packages containing 30 coated tablets.
 
           VIRORREVER®600                                             Efavirenz                                                                                     600 mg tabs. x 30
Made in Argentina
For sale under filed prescriptiontacc-es
Efavirenz
Composition:
 Each tablet contains: Efavirenz 600 mg.
Therapeutic Action:
 Non nucleoside reverse transcriptase inhibitor of reverse transcriptase of the Human Immunodeficiency Virus Type 1 (HIV-1).
Dosing and Administration:
Adults:
 

600 mg administered orally once a day. Concomitant antiretroviral treatment: Efavirenz must be administered in combination with other antiretroviral medications.

 
Adolescents and Children (17 years of ageand younger):
 

Body weight of 13-15 kg: 200 mg. Body weight of 15-20 kg: 250 mg. Body weight of 20-25 kg: 300 mg. Body weight of 25-32.5 kg: 350 mg. Body weight of 32.5-40 kg: 400 mg. The recommended dose for children whose body weight is over 40 kg is 600 mg, once a day.

Presentation:
 Package containing 30 tablets.
 
           VUCLODIR®                                                        Lamivudina                                                                                 150 mg tabs. x 60 / 300 mg tabs. x 30
Made in Argentina
For sale under filed prescriptiontacc-es
Lamivudine
Composition:
 Tablets: Each tablet of VUCLODIR 150 contains: 150 mg Lamivudine. Each coated tablet of VUCLODIR 300 contains: Lamivudine 300 mg
Therapeutic Action:
 Antiviral. Reverse transcriptase inhibitor.
Indications:
 It is indicated in antiretroviral combination therapy for the treatment of adults and children infected with Human Immunodeficiency Virus (HIV).
Dosing and Administration:
Tablets: Therapy should be initiated by a physician experienced in treating HIV infection. Lamivudine may be administered with or without food. To ensure administration of the entire dose, tablets should be swallowed without crushing. Alternatively the tablets may be split and added to a small amount of liquid or semisolid food, which must be taken immediately. Adults and adolescents over 12 years of age: The recommended dose of lamivudine is 300 mg a day. This may be administered as 150 mg twice daily or 300 mg once a day. Patients who changed the pattern of once a day should take 150 mg twice a day and switch to 300 mg once a day the following morning. When a once daily at night pattern is preferred, only 150 mg of lamivudine should be taken on the first morning, followed by 300 mg at night. When changing back to two times a day regime, patients should complete the day treatment and start with 150 mg twice a day the following morning. Children from three months to 12 years of age: The recommended dose is 4 mg / kg twice daily up to a maximum of 300 mg a day.
 
Presentation:
 VUCLODIR 150 mg: packages containing 60 coated tablets. VUCLODIR 300 mg: packages containing 30 coated tablets.
 
           ZEPRIL®                                                              Abacavir                                                                                      300 mg coat. tabs. x 60
Made in Argentina
For sale under filed prescriptiontacc-es
Abacavir
Composition:
 Each coated tablet contains: Abacavir Sulphate (equivalent to 300 mg of Abacavir) 351.4 mg.
Therapeutic Action:
 Antiretroviral drug with a specific action against HIV.
Indications:
 Abacavir is indicated in antiretroviral combination therapy for the treatment of the infection caused by the Human Immunodeficiency Virus (HIV) in adults and children.
Dosing and Administration:
Adults and children:
 

Adults and children older than 12 years of age: 300 mg twice a day. Children from 3 Months to 16 Years of Age: 8 mg/kg twice a day up to a maximum of 600 mg per day. Abacavir may be taken with or without food.

Presentation:
 Package containing 60 coated tablets.
 
           ZETAVUDIN®                                                      Lamivudine / Zidovudine                                                            150 mg / 300 mg coat. tabs. x 60
Made in Argentina
For sale under filed prescriptiontacc-es
Lamivudine-Zidovudine
Composition:
 >Each coated tablet contains: Lamivudine 150 mg; Zidovudine 300 mg.
Therapeutic Action:
 >Antiviral.
Dosing and Administration:
Adults and children:
 

Adults and children older than 12 years of age: The recommended dose of lamivudine/zidovudine is 1 tablet twice a day..

Presentation:
 Package containing 60 coated tablets.
 
           ZETROTAX®                                                       Zidovudine                                                                                   10 mg/ml syrup x 240 ml
Made in Argentina
For sale under filed prescription
Zidovudine (AZT)
Composition:
 Syrup: 10 mg/ml (240 ml)
Therapeutic Action:
 Antiretroviral agent.
Dosing and Administration:
Adults
 

With symptomatic infection, 100 mg (10 ml of syrup) every 4 hours (total daily dose 600 mg). With asymptomatic infection, 100 mg. every 4 hours, while the patient is asleep (total daily dose 600 mg.).

 
Children:
 

from 3 months to 12 years of age, 180 mg/m2 of body surface area, every 6 hours.

Presentation:
Package containing 240 ml bottle
 

Note: Products which are still under patent are manufactured according to Argentinean requirements. Please note that they are delivered only to countries where the substance and  its use are not protected by patents.